Asbestos Cancer, Lung Cancer, and Mesothelioma Clinical Trials

Reviewed By: Bill Mulligan
Last Updated: January 11th, 2009

Asbestos Cancer, Lung Cancer, and Mesothelioma Clinical Trials

Those who have been diagnosed with an asbestos disease – whether its pleural plaques, asbestosis, lung cancer or mesothelioma – know all too well that such diseases have no cure.

The good news is that ongoing research is being carried out on treatments that can both extend life and improve the quality of life for asbestos patients. Some of these treatments are highly complex and involve the administration of pharmaceuticals, new types of chemo-therapy, radiation treatments and other such treatments.

When new treatments show potential, they must go through clinical trials. These are defined by the U.S. Institutes of Health as “biomedical or health-related research studies in human beings that follow a pre-defined protocol.” They may be either interventional, in which research volunteers are assigned to a particular treatment, or observational, in which the volunteer is simply studied by investigators who record the outcomes.

Many promising treatments are currently undergoing clinical trials in all phases.
One such treatment involves a relatively new drug called pemetrexed. This particular drug, currently undergoing a Phase II clinical trial, is a chemotherapy drug marketed under the brand name Alimta. Chemically, this substance is similar to Vitamin B9, or folic acid, which is found in leafy green vegetables. Premetrexed disodium and has been shown to inhibit the growth of tumor cells by stopping the formation of DNA and RNA at the cellular level.

Another chemotherapy drug currently undergoing trials is known as AZD2171, which appears to stop the blood flow that nourishes tumor cells, essentially starving them to death.

Some treatments currently being studied involve the use of simple plants found in the wild or even at the market. For example, Japanese cancer researchers recently found evidence to suggest that the consumption of boysenberries, which have significantly higher levels of anti-oxidants than similar fruit, can actually inhibit the growth of mesothelioma cells. In Australia, a relative of the deadly nightshade plant, known locally as the “Devil’s Apple,” has long been used to treat cancerous lesions on horses; today, medical researchers have identified one of the substances in this plant, which is called SBP002, as that which seems to have an effect on cancer cells. Like AZD2171, this particular chemical appears to interfere with the reproduction process of cancer cells.

One of the most exciting and promising treatments now in a Phase II study involves the use of a substance produced naturally in the human body. Known as antineoplaston, this chemical is a natural ingredient of human blood and urine; as an isolate, it has shown some promise in the treatment of mesothelioma among other types of cancers.

Participation in clinical trials are not for everyone. Although they are a necessary part of medical research and can yield great benefit both to the patient and to society, there are always some risks involved. In addition, most trials have specific criteria which potential subjects must meet; these differ from one trial to another.

Although clinical trials are regulated by both the law and a code of professional ethics, anyone who is considering participation in a clinical trial should learn as much as possible beforehand. Here, you will find much of the information you will need in order to make an educated decision.


Current Clinical Trials Covered on Asbestos.net:


Capecitabine (Xeloda) in Malignant Mesothelioma: A Phase II Study
Status: Active
Condition: Malignant Mesothelioma
Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma
Status: Recruiting
Condition: Malignant Mesothelioma
Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma
Status: Active
Condition: Malignant Mesothelioma
Tomotherapy Treatment for Mesothelioma
Status: Recruiting
Condition: Mesothelioma
Phase II Study of AZD2171 (NSC#732208) in Patients With Malignant Mesothelioma
Status: Recruiting
Condition: Malignant Mesothelioma
Phase II Study on Tomusex in Malignant Mesothelioma
Status: Active
Condition: Malignant Mesothelioma
Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Status: Recruiting
Condition: Carcinoma, Non-Small-Cell Lung; Mesothelioma
Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Mesothelioma
Status: Recruiting
Condition: Malignant Mesothelioma
Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma
Status: Active
Condition: Breast Cancer; Endometrial Cancer; Malignant Mesothelioma
A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma
Status: Active
Condition: Malignant Mesothelioma; Perioperative/Postoperative Complications; Quality of Life
Prospective Evaluation of Epigenetic Alterations in Patients With Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Status: Recruiting
Condition: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma
Mesothelioma and Radical Surgery Trial
Status: Recruiting
Condition: Malignant Mesothelioma
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Thoracic and Myeloid Neoplasms
Status: Recruiting
Condition: Leukemia; Lung Cancer; Malignant Mesothelioma; Myelodysplastic Syndromes; Peritoneal Cavity Cancer
Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients
Status: Completed
Condition: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion in Subjects With Pulmonary and Pleural Malignancies
Status: Recruiting
Condition: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid
Status: Recruiting
Condition: Non-Small Cell Lung Cancer; Mesothelioma; Lung Neoplasms
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Novel Flavopiridol in Patients With Refractory Solid Tumors and Hematologic Malignancies
Status: Terminated
Condition: Breast Cancer; Head and Neck Cancer; Intraocular Melanoma; Kidney Cancer; Leukemia; Lung Cancer; Lymphoma; Malignant Mesothelioma; Melanoma (Skin); Multiple Myeloma and Plasma Cell Neoplasm; Sarcoma; Small Intestine Cancer
The Detection of Tumor Hypoxia and Vascularity in Patients Undergoing Intraperitoneal Photodynamic Therapy
Status: Completed
Condition: Malignant Mesothelioma; Metastatic Cancer; Peritoneal Cavity Cancer
Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing
Status: Completed
Condition: Cervical Cancer; Fallopian Tube Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity CancerCervical Cancer; Fallopian Tube Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity Cancer
Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies
Status: Completed
Condition: Adrenocortical Carcinoma; Brain and Central Nervous System Tumors; Head and Neck Cancer; Liver Cancer; Malignant Mesothelioma; Pheochromocytoma; Sarcoma
Phase I and Clinical Pharmacologic Study of Inhaled Doxorubicin in Adults With Advanced Solid Tumors Affecting the Lungs
Status: Completed
Condition: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Thymoma and Thymic Carcinoma
Phase I Study Of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum
Status: Recruiting
Condition: Esophageal Cancer; Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas
Status: Active
Condition: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Malignant Mesothelioma; Pancreatic Cancer; Small Intestine Cancer
Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days
Status: Completed
Condition: Cervical Cancer; Fallopian Tube Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity Cancer
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Meso
Status: Completed
Condition: Malignant Pleural Mesotherioma
Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment
Status: Recruiting
Condition: Breast Cancer; Colorectal Cancer; Lung Cancer; Malignant Mesothelioma; Prostate Cancer; Psychosocial Effects/Treatment; Quality of Life; Thymoma and Thymic Carcinoma
A Trial of Active Intralymphatic Immunotherapy With Interferon-Treated Cells and Cyclophosphamide
Status: Active
Condition: Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer
Radiofrequency Ablation of Pulmonary Malignancy
Status: Active
Condition: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Thymoma and Thymic Carcinoma
A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Status: Recruiting
Condition: Malignant Epithelial Mesothelioma; Adenocarcinoma of the Pancreas; Non-Small Cell Lung Carcinoma; Adenocarcinoma of the Ovaries
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Status: Recruiting
Condition: Ovarian Neoplasms; Colorectal Neoplasms; Melanoma; Small Cell Lung Cancer; Liposarcoma
A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease
Status: Recruiting
Condition: Peritoneal Neoplasms; Retroperitoneal Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma; Neuroblastoma; Ovarian Neoplasms; Sarcoma; Adrenocortical Carcinoma; Wilms Tumor; Rhabdomyosarcoma; Desmoplastic Small Round Cell Tumor
 

Loading Video...
requires flash
This article is part of the Asbestos.net 'Watch This Article' Series: A collection of our in-depth and informative articles that have been recorded as high quality videos to allow for ease of access by all of our visitors.

 

    - Return To Top

 

    - Return To Top

 

    - Return To Top

 

    - Return To Top

 
Asbestos Cancer & Mesothelioma Support Center
Asbestos & Mesothelioma Book